KRAS and non-small cell lung carcinoma: Figure 3A shows that the frequency of positive PD-L1 expression was marginally significantly higher for NSCLC patients with KRAS mutations (OR = 0.52; 95% CI: 0.31–0.89; P = 0.02; Figure 3A).